The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.
The sexually transmitted infection are increasing worldwide, with estimates suggesting over 82 million new cases annually. Especially elevated rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.
“The authorization of fresh medications for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the very limited treatment choices presently on offer.”
Medical experts are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.
Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that specific application of this new drug will help delay the development of resistance.
Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.
Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.
“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”
Based on data detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which involves two antibiotics. The research enrolled nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.
As part of the agreement of its unique model, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.
Medical professionals treating patients have shared hope. The availability of a easy-to-administer therapy like this is hailed as a "game-changer" for managing the epidemic. This is viewed as essential to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.
A tech enthusiast and gaming aficionado with over a decade of experience in digital media and content creation.
News